These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23799328)

  • 1. Body composition in chemotherapy: the promising role of CT scans.
    Prado CM
    Curr Opin Clin Nutr Metab Care; 2013 Sep; 16(5):525-33. PubMed ID: 23799328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early detection of cancer therapeutics-related cardiac dysfunction].
    Potier A; Ederhy S; Ancedy Y; Etienney A; Soulat-Dufour L; Chauvet M; Hollebecque A; Adavane-Scheuble S; Boccara F; Soria JC; Cohen A
    Bull Cancer; 2016; 103(7-8):667-73. PubMed ID: 27417336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taking cancer-drug toxicity to heart.
    Rose S
    Cancer Discov; 2013 Feb; 3(2):132. PubMed ID: 23400461
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    P J G; A M; L M; H J H; M K; S B; N M
    Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
    Prado CM; Maia YL; Ormsbee M; Sawyer MB; Baracos VE
    Anticancer Agents Med Chem; 2013 Oct; 13(8):1197-203. PubMed ID: 23919745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C; Alasker A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 14. The emerging role of computerized tomography in assessing cancer cachexia.
    Prado CM; Birdsell LA; Baracos VE
    Curr Opin Support Palliat Care; 2009 Dec; 3(4):269-75. PubMed ID: 19667996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
    Rexer H;
    Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
    Barney BM; Markovic SN; Laack NN; Miller RC; Sarkaria JN; Macdonald OK; Bauer HJ; Olivier KR
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):73-80. PubMed ID: 23920388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 18. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity.
    Prado CM; Antoun S; Sawyer MB; Baracos VE
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):250-4. PubMed ID: 21415735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
    J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.